还原型谷胱甘肽联合复明片治疗早期老年性白内障的临床观察

目的:观察还原型谷胱甘肽联合复明片治疗早期老年性白内障的临床疗效和安全性。方法:180例早期老年性白内障患者按随机数字表法均分为对照组和试验组。对照组患者给予还原型谷胱甘肽滴眼液1²滴/次,4次/d+维生素E片30 mg/次,口服,3次/d+维生素C片0.3 g/次,口服,3次/d;试验组患者在对照组治疗的基础上给予复明片5片/次,口服,3次/d。两组患者疗程均为2个月。观察两组患者的临床疗效,治疗前后裸眼视力分布,晶体混浊改善情况及不良反应发生情况。结果:治疗后试验组患者总有效率、晶体混浊明显吸收、部分吸收眼数显著高于对照组,两组比较差异均有统计学意义(P<0.05)。两组患者治疗前裸眼视力比较,差异无统计学意义(P>0.05);治疗后两组患者裸眼视力好转眼数均显著优于同组治疗前,且试验组优于对照组,差异有统计学意义(P<0.05)。试验组患者不良反应发生率显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论:还原型谷胱甘肽联合复明片治疗早期老年性白内障较单用还原型谷胱甘肽疗效更显著,且安全性较好。

Clinical Observation of Reduced Glutathione Combined with Fuming Tablets in the Treatment of Early Senile Cataract

OBJECTIVE：To observe clinical efficacy and safety of reduced glutathione combined with Fuming tablets in the treatment of early senile cataract. METHODS：180 patients with early senile cataract were randomized into control group and control group. Control group was given Reduced glutathione eye drops 1-2 drops/time 4 times a day,Vitamin E tablet 30 mg/time,po,3 times a day and Vitamin C tablet 0.3 g/time,po,3 times a day. On the basis of control group,trial group was additionally given Fuming tablets 5 tablets/ time,3 times a day. Treatment course of 2 groups lasted for 2 months. Clinical efficacy,distribution of naked vision,the improvement of lens turbidity and ADR were observed between 2 groups. RESULTS：The total effective rate,the absorption of lens turbidity and the number of partial absorption eyes in trial group were significantly higher than in control group;there was statistical significance（P〈0.05）. There was no statistical significance in naked eye vision in 2 groups before treatment（P〉0.05）. The number of eyes with improved naked eye vision in 2 groups after treatment was significantly better than before,and the trial group was better than the control group;there was statistical significance（P〈0.05）. The incidence of ADR in trial group was significantly lower than in control group;there was statistical significance（P〈0.05）. CONCLUSIONS：Reduced glutathione combined with fuming tablets is more effective and safer than reduced glutathione alone in the treatment of early senile cataract.